Clinical trials: ER+ / HER2- Advanced Breast Cancer
The Neoadjuvant Therapy
The Neoadjuvant Combined Hormone Therapy in Premenopausal Women With Locally Advanced ER+/HER2- Breast Cancer
Breast cancer take a leading position in the structure of morbidity and mortality from malignant tumors among women. Today the interest of many scientists and pharmaceutical companies is focused on the study of metastatic breast…
- Trial name
- NCT04753177
- Testing
- Ribocyclib, fulvestrant, triptorelin, Doxorubicin, cyclophosphamide, paclitaxel
- Where
- Russia
- Volunteers
- 120 people
- Sponsor
- Saint Petersburg State Budgetary Healthcare Institution, City Clinical Oncology Dispensary
ER Positive, HER2 Negative Breast Cancer Neoplasms
Investigating Patient Satisfaction With Oral Anti-cancer Treatment in Patients With Hormone-receptor Positive, HER2-receptor Negative, Advanced Breast Cancer
A prospective, non-interventional, non-controlled multicenter observational study to evaluate aspects of pharmaceutical care and the treatment of postmenopausal patients with hormone-receptor positive, HER2-receptor negative…
- Trial name
- IPSOC-mamma (NCT02875951)
- Where
- Belgium
- Volunteers
- 100 people
- Sponsor
- KU Leuven
Breast Neoplasms
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
The purpose of this study is to assess the efficacy and safety of iza-bren, a bi-specific antibody-drug conjugate against EGFR and HER3 with a topoisomerase inhibitor payload versus treatment of physician's choice (TPC)…
- Trial name
- NCT06926868
- Testing
- Iza-bren, Nab-paclitaxel, Paclitaxel
- Where
- 295 sites in United States, Argentina and 26 more
- Volunteers
- 600 people
- Sponsor
- Bristol-Myers Squibb